Erscheint 6 Ausgaben pro Jahr
ISSN Druckformat: 0743-4863
ISSN Online: 2162-660X
Indexed in
Inhalational Therapy for Pulmonary Arterial Hypertension: Current Status and Future Prospects
ABSTRAKT
This review summarizes the pathophysiology and current therapeutic and drug delivery strategies for pulmonary arterial hypertension (PAH), a rare but devastating disorder of the pulmonary circulation affecting 50,000 to 100,000 persons in the United States. Chief clinical features of PAH include increased mean pulmonary arterial pressure (>25 mm Hg) and right ventricular and smooth muscle hypertrophy. A wide variety of agents have been studied for use as anti-PAH drugs, including prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors, to name a few. However, a major shortcoming of anti-PAH medications is their short half-lives, requiring them to be administered via parenteral routes, which lead to undesirable side effects, including systemic vasodilation. Inhalational delivery of anti-PAH drugs provides an attractive alternative to conventional routes, with ease of administration and minimal systemic vasodilation. Recently, the U.S. Food and Drug Administration approved inhalable iloprost (Ventavis®), a prostacyclin analogue, for PAH treatment. Other drugs being studied for their potential in inhalable PAH therapy include PGE1, treprostinil, vasoactive intestinal peptide, and fasudil. Controlled-release inhalable delivery systems for anti-PAH medications have also been proposed to facilitate long-term and selective vasodilation of pulmonary arteries. Extensive studies are warranted to develop safe and effective drug delivery systems that will provide a better quality of life to patients.
-
Gupta Vivek, Gupta Nilesh, Shaik Imam H., Mehvar Reza, McMurtry Ivan F., Oka Masahiko, Nozik-Grayck Eva, Komatsu Masanobu, Ahsan Fakhrul, Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension, Journal of Controlled Release, 167, 2, 2013. Crossref
-
Mosgoeller W., Prassl R., Zimmer A., Nanoparticle-Mediated Treatment of Pulmonary Arterial Hypertension, in Nanomedicine - Cancer, Diabetes, and Cardiovascular, Central Nervous System, Pulmonary and Inflammatory Diseases, 508, 2012. Crossref
-
Arumpanayil Angela, Inhaled Epoprostenol to Support the Severely Hypoxemic Patient With Acute Respiratory Distress Syndrome, Dimensions of Critical Care Nursing, 32, 5, 2013. Crossref
-
Gupta Nilesh, Ibrahim Hany M., Ahsan Fakhrul, Peptide–Micelle Hybrids Containing Fasudil for Targeted Delivery to the Pulmonary Arteries and Arterioles to Treat Pulmonary Arterial Hypertension, Journal of Pharmaceutical Sciences, 103, 11, 2014. Crossref
-
Patel Brijeshkumar, Gupta Nilesh, Ahsan Fakhrul, Particle engineering to enhance or lessen particle uptake by alveolar macrophages and to influence the therapeutic outcome, European Journal of Pharmaceutics and Biopharmaceutics, 89, 2015. Crossref
-
Uña Orejón R., Altit Millán E., Aguar Fernández M., Ureta Tolsada M.P., Paraganglioma productor de catecolaminas en una paciente con síndrome de Eisenmenger y ventrículo único. Interés de la administración de óxido nítrico y monitorización hemodinámica mínimamente invasiva, Revista Española de Anestesiología y Reanimación, 63, 3, 2016. Crossref
-
Vaidya Bhuvaneshwar, Gupta Vivek, Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery, Journal of Controlled Release, 211, 2015. Crossref
-
Gupta Vivek, Ahsan Fakhrul, Influence of PEI as a core modifying agent on PLGA microspheres of PGE1, a pulmonary selective vasodilator, International Journal of Pharmaceutics, 413, 1-2, 2011. Crossref
-
Shoemaker Ritchie C., House Dennis, Ryan James C., Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) acquired following exposure to water-damaged buildings, Health, 05, 03, 2013. Crossref
-
Dabbagh Ali, Postoperative Respiratory Management in Pediatric Cardiac Surgical Patients, in Congenital Heart Disease in Pediatric and Adult Patients, 2017. Crossref
-
Hecker Louise, Mechanisms and consequences of oxidative stress in lung disease: therapeutic implications for an aging populace, American Journal of Physiology-Lung Cellular and Molecular Physiology, 314, 4, 2018. Crossref
-
Ofman Gaston, Tipple Trent E., Antioxidants & bronchopulmonary dysplasia: Beating the system or beating a dead horse?, Free Radical Biology and Medicine, 142, 2019. Crossref
-
Kwon Yong-Bin, Kang Ji-Hyun, Han Chang-Soo, Kim Dong-Wook, Park Chun-Woong, The Effect of Particle Size and Surface Roughness of Spray-Dried Bosentan Microparticles on Aerodynamic Performance for Dry Powder Inhalation, Pharmaceutics, 12, 8, 2020. Crossref
-
Gupta Vivek, Gupta Nilesh, Shaik Imam H., Mehvar Reza, Nozik-Grayck Eva, McMurtry Ivan F., Oka Masahiko, Komatsu Masanobu, Ahsan Fakhrul, Inhaled PLGA Particles of Prostaglandin E1 Ameliorate Symptoms and Progression of Pulmonary Hypertension at a Reduced Dosing Frequency, Molecular Pharmaceutics, 10, 5, 2013. Crossref
-
Brunner Nathan, Perez Vinicio A. de Jesus, Richter Alice, Haddad François, Denault André, Rojas Vanessa, Yuan Ke, Orcholski Mark, Liao Xiaobo, Perioperative Pharmacological Management of Pulmonary Hypertensive Crisis during Congenital Heart Surgery, Pulmonary Circulation, 4, 1, 2014. Crossref
-
Xu Hongfei, Ji Hongyu, Li Zerong, Qiao Wenmei, Wang Chenghao, Tang Jingling, In vivo Pharmacokinetics and in vitro Release of Imatinib Mesylate-Loaded Liposomes for Pulmonary Delivery, International Journal of Nanomedicine, Volume 16, 2021. Crossref
-
Al-Hilal Taslim A., Hossain Mohammad Anwar, Alobaida Ahmed, Alam Farzana, Keshavarz Ali, Nozik-Grayck Eva, Stenmark Kurt R., German Nadezhda A., Ahsan Fakhrul, Design, synthesis and biological evaluations of a long-acting, hypoxia-activated prodrug of fasudil, a ROCK inhibitor, to reduce its systemic side-effects, Journal of Controlled Release, 334, 2021. Crossref
-
Mohamed Nura A., Marei Isra, Crovella Sergio, Abou-Saleh Haissam, Recent Developments in Nanomaterials-Based Drug Delivery and Upgrading Treatment of Cardiovascular Diseases, International Journal of Molecular Sciences, 23, 3, 2022. Crossref